Early Phase 1
N=76
Autonomic Neuropathy, GI Motility, and Inflammation in HIV
HIV Disease
Bottom Line
View on ClinicalTrials.gov: NCT02850276 ↗Enrolled (actual)
76
Serious AEs
0.0%
Results posted
May 2019
Primary outcome: Primary: Change in Breath Test — 28; 14 ppm
Study Design & Population
- Study type
- Interventional
- Phase
- Early Phase 1
- Interventions
- Pyridostigmine (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Primary completion
- Jun 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Breath Test |
28; 14 | — |
| PRIMARY Number of Participants With Reduction in Small Intestinal Bacterial Overgrowth (SIBO) |
13 | — |
| SECONDARY Mean Percent Retention of Gastric Contents on Gastric Emptying Study |
3; 2 | — |
| SECONDARY Change in sCD14 Level |
2573; 2095 | — |
| SECONDARY Change in TNFα Level |
134.0; 117.5 | — |
| SECONDARY Change in IL-6 Plasma Level |
30.5; 26.5 | — |
| SECONDARY The Composite Autonomic Symptom Score (COMPASS) |
8; 8.6 | — |
| SECONDARY Medical Outcomes Study Questionnaire |
66.1; 65 | — |
Summary
The purpose of this study is to explore a possible link between the autonomic nervous system and immune function in patients with HIV. Sometimes HIV can cause these nerves to function abnormally, this is called HIV-associated autonomic neuropathy (HIV-AN). HIV-AN is a condition that is different from person to person. In some people it causes no symptoms and is not harmful, in others it may cause symptoms such as dizziness or lightheadedness, nausea, vomiting, diarrhea, constipation, or problems urinating. Most people with HIV-AN don't know that they have it. One of the important nerves in the autonomic nervous system is the vagus nerve. Abnormal function of the vagus nerve may cause stomach and intestinal slowing, which could lead to an overgrowth of bacteria. The body senses these bacteria and tries to fight them, leading to inflammation.
In this study the researchers will test whether abnormal function of the vagus nerve in HIV is associated with stomach slowing and overgrowth of bacteria, and if a drug called pyridostigmine can help.
Eligibility Criteria
Inclusion Criteria
- ≥18 years old
- Documented evidence of HIV-1 infection
- Stable CART therapy for ≥3 months Most recent HIV-1 viral load ≤100 copies/ml (value must be within the past six months)
- English speaking
- Able to tolerate autonomic testing (e.g. able to stand, able to perform Valsalva maneuver).
- If using nicotine-containing products willing to refrain from use for 24 hours prior to all testing procedures (autonomic reflex screen, breath testing, and gastric emptying)
- ≥1 GI symptom on the Survey of Autonomic Symptoms (SAS)47
Exclusion Criteria
- Diagnosis known to cause autonomic dysfunction other than HIV (e.g. Parkinson's disease, diabetes)
- Diagnosis known to cause GI dysfunction other than HIV (e.g. peptic ulcer disease, infectious diarrhea)
- Current use of any of the following classes of medications (due to potential for significant autonomic or GI effects, interaction with pyridostigmine, or interference with one or more of the testing procedures) Prokinetics (e.g. metoclopramide) Anti-diarrheals (e.g. loperamide) Antibiotics Mefloquine
- Medical or psychiatric conditions precluding safe participation in study procedures or deemed likely to result in hospitalization during the study period.
- The presence of one or more of the following diagnoses which render the Valsalva maneuver relatively or absolutely contraindicated: uncontrolled glaucoma, aortic stenosis, myocardial infarction in the last 6 months, other retinopathy or unclipped cerebral aneurysm.
- The presence of one or more of the following diagnoses which impede interpretation of autonomic testing: cardiac arrhythmias or pacemakers.
- An allergy to eggs (contraindication to gastric emptying scintigraphy)
- Any of the following laboratory results:
Positive pregnancy test (administered to women of childbearing potential only) Urine toxicology screen positive for stimulants (e.g. amphetamines, cocaine) or opiates/opioids.
Data sourced from ClinicalTrials.gov (NCT02850276). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.